The use of advanced biological and tissue-engineered wound products.
This article aims to reintroduce readers to biologically based and tissue-engineered wound management products. Indications for their use in clinical practice are suggested. It also examines two well-established wound management interventions, topical negative pressure therapy and larval therapy, which could have a positive effect on the outcome of biologically based and tissue-engineered wound management products.
Collier
Mark
M
United Lincolnshire Hospitals NHS Trust, Boston, Lincolnshire. mark.collier@ulh.nhs.uk
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D001685:Biological Factors / Q000627:therapeutic use*; D002482:Cellulose / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use; D003094:Collagen / Q000627:therapeutic use; D003646:Debridement; D004175:Diptera; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D015603:Keratinocytes / Q000502:physiology; D007814:Larva; D017592:Skin Care / Q000379:methods*; D017768:Skin, Artificial / Q000706:statistics & numerical data; D013396:Suction; D023822:Tissue Engineering / Q000379:methods / Q000706:statistics & numerical data; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology; D014947:Wounds and Injuries / Q000628:therapy*
D000276:Adjuvants, Immunologic; C440568:Alloderm; C117898:Apligraf; D001685:Biological Factors; D020099:Coated Materials, Biocompatible; D036341:Intercellular Signaling Peptides and Proteins; C512800:TransCyte; C114835:integra artificial skin; D002482:Cellulose; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates; D003094:Collagen